A new cancer drug costs $2 to manufacture per dose but is priced at $10,000 per dose. Critics call this price gouging. What is the economic argument for why the price exceeds marginal cost?
AThe manufacturer is a monopolist and should be regulated to price at marginal cost
BThe $10,000 price must cover the fixed costs of R&D (averaging $1-2 billion per approved drug, including failed candidates), and marginal cost pricing would eliminate the incentive to invest in future drug development
CThe price is set by supply and demand — high demand for cancer drugs drives prices up
DManufacturing costs are actually $10,000 per dose when quality control is included
Pharmaceutical pricing reflects the fundamental tension between access and innovation. The marginal cost of production is negligible, but the fixed costs of discovery and clinical development are enormous — and most drug candidates fail, so successful drugs must cover the losses from failures. Pricing at marginal cost would make drug development unprofitable, and no new drugs would be developed. The patent system's solution is temporary monopoly pricing to allow cost recovery, followed by generic competition at near-marginal cost. Whether any specific price is 'fair' depends on how much of the revenue funds genuine R&D versus marketing, executive compensation, or profit redistribution.
Question 2 True / False
After a brand-name drug's patent expires, generic entry typically reduces the price by 80-90% within a few years. This demonstrates that pharmaceutical markets become highly competitive once patent protection ends.
TTrue
FFalse
Answer: True
Generic drugs contain the same active ingredient, dosage, and bioavailability as the original. Once the patent barrier is removed, multiple manufacturers can produce the drug at near-marginal cost, and price competition drives prices down dramatically. The US generic market has dozens of competitors for popular drugs, with prices sometimes falling to pennies per dose. This confirms that the high brand-name price reflects monopoly rents from patent protection, not inherent production costs. However, some strategies (pay-for-delay settlements, patent evergreening, complex formulations) can delay generic entry beyond the original patent term.
Question 3 Short Answer
Explain why pharmaceutical companies charge different prices for the same drug in different countries, and whether this price discrimination improves or reduces global welfare.
Think about your answer, then reveal below.
Model answer: Price discrimination allows companies to charge higher prices in wealthy countries (where willingness and ability to pay are high) and lower prices in poor countries (where high prices would eliminate access entirely). This increases global access — patients in India can afford a drug at $100 that Americans pay $10,000 for. It can improve global welfare if the alternative is a uniform price that either makes the drug unaffordable in poor countries (high uniform price) or unprofitable to develop (low uniform price). However, it also means wealthy country consumers subsidize global access, and political pressure for reference pricing (tying prices across countries) can undermine the differential pricing that enables access in low-income settings.
The welfare analysis is complex. Ramsey pricing theory suggests that optimal pricing for a product with high fixed costs and low marginal costs involves charging more to less price-sensitive buyers (wealthy countries) and less to more price-sensitive buyers (poor countries). This approximates the pharmaceutical pricing pattern observed globally. International reference pricing policies that force prices toward the lowest available price can actually harm low-income country access if manufacturers raise their prices in those countries to avoid depressing reference prices elsewhere.